MyChesCo on MSN13h
Endo, Inc. Shares Positive Data on XIAFLEX Treatment for Peyronie’s Disease
Endo, Inc. (OTCQX: NDOI) revealed new insights from a post hoc data analysis of its Phase 3 clinical trial of XIAFLEX® ...
The Manila Times14h
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...
Targeted Oncology14h
Velcheti Evaluates Activity of Repotrectinib for ROS1 Fusion–Positive NSCLC
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...